Effect of diquafosol ophthalmic solution on the optical quality of the eyes in patients with aqueous-deficient dry eye

Acta Ophthalmol. 2014 Dec;92(8):e671-5. doi: 10.1111/aos.12443. Epub 2014 May 25.

Abstract

Purpose: To investigate the short- and long-term effects of diquafosol ophthalmic solution on the optical quality of the eyes in patients with aqueous-deficient dry eye.

Methods: Sixteen eyes in 16 patients with mild or moderate aqueous-deficient dry eye were treated with 3% diquafosol ophthalmic solution. Ocular higher-order aberrations (HOAs) were measured with a wavefront sensor before and at 15 min after diquafosol instillation at the baseline visit and at 4 weeks after treatment initiation. Dry eye symptoms, tear break-up time (BUT), corneal/conjunctival fluorescein staining and Schirmer's test were also evaluated before and after treatment with diquafosol.

Results: Treatment with diquafosol ophthalmic solution significantly improved dry eye symptoms, corneal staining and BUT. Compared with mean total HOAs at baseline (0.180 ± 0.06 μm), those at 4 weeks after treatment significantly decreased (0.148 ± 0.039 μm; p = 0.035), whereas those 15 min after diquafosol instillation at the baseline visit did not change significantly (0.170 ± 0.049 μm; p = 0.279).

Conclusions: Although no significant change in HOAs was observed as a short-term effect of a single-drop instillation of diquafosol, long-term use of diquafosol to treat aqueous-deficient dry eye reduced HOAs as well as improved corneal epithelial damage and tear film stability.

Keywords: diquafosol ophthalmic solution; dry eye; higher-order aberrations; tear film.

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Topical
  • Aged
  • Aqueous Humor / metabolism*
  • Corneal Wavefront Aberration / physiopathology*
  • Female
  • Humans
  • Keratoconjunctivitis Sicca / drug therapy*
  • Keratoconjunctivitis Sicca / metabolism
  • Keratoconjunctivitis Sicca / physiopathology
  • Male
  • Middle Aged
  • Ophthalmic Solutions
  • Polyphosphates / therapeutic use*
  • Purinergic P2Y Receptor Agonists / therapeutic use*
  • Sjogren's Syndrome / drug therapy*
  • Sjogren's Syndrome / metabolism
  • Sjogren's Syndrome / physiopathology
  • Surveys and Questionnaires
  • Tears / chemistry
  • Uracil Nucleotides / therapeutic use*

Substances

  • Ophthalmic Solutions
  • Polyphosphates
  • Purinergic P2Y Receptor Agonists
  • Uracil Nucleotides
  • diquafosol